{"articles":[{"id":"cmqnei92y001ip008t2v4k9bl","exaId":"https://www.prnewswire.com/news-releases/curegene-achieves-first-participant-dosed-in-us-pivotal-trial-for-evategrel-cg-0255-a-best-in-class-antiplatelet-drug-accelerating-global-commercialization-302805841.html","title":"CureGene Achieves First Participant Dosed in U.S. Pivotal Trial for Evategrel (CG-0255), a Best-in-Class Antiplatelet Drug, Accelerating Global Commercialization","url":"https://www.prnewswire.com/news-releases/curegene-achieves-first-participant-dosed-in-us-pivotal-trial-for-evategrel-cg-0255-a-best-in-class-antiplatelet-drug-accelerating-global-commercialization-302805841.html","source":"www.prnewswire.com","author":"CureGene","publishedAt":"2026-06-21T00:00:00.000Z","summary":"CureGene Achieves First Participant Dosed in U.S. Pivotal Trial for Evategrel (CG-0255), a Best-in-Class Antiplatelet Drug, Accelerating Global Commercialization Accessibility Statement Skip Navigation\n\nSHANGHAI, June 20, 2026 /PRNewswire/ -- CureGene Pharmaceutical today announced that the first participant has been successfully dosed in the U.S. pivotal clinical trial of Evategrel (CG-0255), its proprietary new-generation best-in-class antiplatelet agent. This milestone marks a critical step toward the New Drug Application (NDA) submission in the United States and brings new hope to millions of patients with cardiovascular and cerebrovascular diseases worldwide.\n\nEvategrel (CG-0255) is the leading asset developed from CureGene's proprietary A-proX™ Prodrug Platform. It is the world's fir","domain":"CLINICAL_TRIALS","significance":"CureGene Pharmaceutical announced that the first participant has been dosed in the U.S. pivotal trial of Evategrel (CG-0255), its proprietary A-proX-derived antiplatelet candidate, a regulatory milestone that advances the program toward NDA submission. In The Last Economy frame, this is the phase-transition point where drug discovery stops being purely empirical and becomes an engineering discipline: the real test is whether increasingly intelligent design pipelines—AI-assisted or not—can convert molecular hypotheses into clinically validated interventions at scale.","createdAt":"2026-06-21T06:23:59.099Z","updatedAt":"2026-06-21T06:23:59.099Z"},{"id":"cmql9n32r001hu808org6rosa","exaId":"https://www.nature.com/articles/s41564-026-02408-1","title":"Deep learning reveals antimicrobial peptides within prions | Nature Microbiology","url":"https://www.nature.com/articles/s41564-026-02408-1","source":"www.nature.com","author":null,"publishedAt":"2026-06-19T00:00:00.000Z","summary":"Deep learning reveals antimicrobial peptides within prions | Nature Microbiology\n\nDownload PDF\n\n### Subjects\n\n- Antimicrobials\n- Microbiology\n\n## Abstract\n\nPrion and prion-like proteins are classically associated with protein misfolding, but amyloidogenic sequences can also participate in host defence. Here, using deep learning, we screened 19.3 million fragments from 2,897 curated prion-related proteins and identified 1,179 candidate antimicrobial peptides, which we term prionins. Among 75 synthesized prionins, 59 inhibited bacterial pathogens, 53 perturbed membranes and 2 reduced Acinetobacter baumannii infection burden in mice.\n\n## Main\n\nPrions are best known for templated conformational conversion and neurodegeneration, yet amyloidogenic proteins are increasingly viewed as functionally","domain":"AMR","significance":"In *Nature Microbiology*, researchers used deep learning to scan 19.3 million fragments from 2,897 curated prion-related proteins and identified 1,179 candidate antimicrobial peptides, or “prionins”; among 75 synthesized hits, 59 inhibited bacterial pathogens, 53 disrupted membranes, and 2 reduced *Acinetobacter baumannii* infection burden in mice. The significance is intelligence inversion: sequences long treated as pathological were computationally mined for functional therapeutic motifs, reframing infection biology as a sequence-to-function engineering problem. It is a concrete step in the larger AI-for-cure trajectory—less brute-force screening, more model-guided discovery across neglected biochemical space, which is how a field approaches phase transition.","createdAt":"2026-06-19T18:32:14.164Z","updatedAt":"2026-06-19T18:32:14.164Z"},{"id":"cmql9n8gg001iu808z5iajgyq","exaId":"https://www.biospace.com/press-releases/portal-biotechnologies-accelerates-growth-with-latest-round-led-by-nfx-expanded-darpa-contract-and-broad-adoption-across-top-pharma-and-academic-centers","title":"Portal Biotechnologies Accelerates Growth with Latest Round Led by NFX, Expanded DARPA Contract, and Broad Adoption Across Top Pharma and Academic Centers - BioSpace","url":"https://www.biospace.com/press-releases/portal-biotechnologies-accelerates-growth-with-latest-round-led-by-nfx-expanded-darpa-contract-and-broad-adoption-across-top-pharma-and-academic-centers","source":"www.biospace.com","author":null,"publishedAt":"2026-06-19T00:00:00.000Z","summary":"Portal Biotechnologies Accelerates Growth with Latest Round Led by NFX, Expanded DARPA Contract, and Broad Adoption Across Top Pharma and Academic Centers - BioSpace\n\nSUBSCRIBE\n\nPress Releases\n\n# Portal Biotechnologies Accelerates Growth with Latest Round Led by NFX, Expanded DARPA Contract, and Broad Adoption Across Top Pharma and Academic Centers\n\nJune 19, 2026 |\n\n3 min read\n\n- Oversubscribed $9M round to underpin rapid platform expansion across drug discovery, AI data generation, and cell therapy manufacturing\n- Portal surpasses over 100 customers to date, including public highlights by Microsoft, Merck, AbbVie, Mass General Brigham, Ragon Institute, and Purdue University\n- Expanded on initial $8M DARPA award with Embedded Entrepreneur Initiative (EEI) contract to supercharge commercial","domain":"FUNDING","significance":"Portal Biotechnologies said it closed an oversubscribed $9 million round led by NFX, expanded its DARPA EEI contract beyond the initial $8 million award, and surpassed 100 customers across pharma and academic centers, including Microsoft, Merck, AbbVie, Mass General Brigham, the Ragon Institute, and Purdue. The significance is that Portal is building enabling infrastructure for AI-driven drug discovery and cell-therapy manufacturing by generating the biological data and experimental throughput that convert model predictions into actionable interventions. In Last Economy terms, this is intelligence inversion in practice: a phase transition from treating disease as a descriptive scientific problem to an engineering problem with controllable inputs, outputs, and feedback loops.","createdAt":"2026-06-19T18:32:21.137Z","updatedAt":"2026-06-19T18:32:21.137Z"},{"id":"cmqlmgzey001fo308g0s1x454","exaId":"https://atari800xl.org/article/every-cure-s-drug-repurposing-strategy-a-new-approach-to-rare-disease-treatment","title":"Every Cure's Drug Repurposing Strategy: A New Approach to Rare Disease Treatment (2026)","url":"https://atari800xl.org/article/every-cure-s-drug-repurposing-strategy-a-new-approach-to-rare-disease-treatment","source":"atari800xl.org","author":null,"publishedAt":"2026-06-19T00:00:00.000Z","summary":"Every Cure's Drug Repurposing Strategy: A New Approach to Rare Disease Treatment (2026)\n\n{ style = event.detail.style; message = event.detail.message; show = true; }); \">\n\n# Every Cure's Drug Repurposing Strategy: A New Approach to Rare Disease Treatment (2026)\n\nTable of Contents\n\nRare diseases aren’t rare in reality The “two ways” of repurposing—and the one everyone avoids End-to-end work, not publication theater AI speeds the search—but validation still decides the fate Repurposing isn’t a replacement—it’s a parallel track The uncomfortable problem: old drugs can be unprofitable to revive Regulatory reality: the sponsor model doesn’t fit the mission Funding choices reveal what the strategy truly values The Bachmann-Bupp example: proof of concept, not a finish line Where this could go nex","domain":"DRUG_REPURPOSING","significance":"Every Cure said it is building an end-to-end, AI-assisted drug-repurposing pipeline for rare disease: use machine intelligence to scan existing approved compounds, prioritize candidates like the Bachmann-Bupp case, and then push them through experimental and clinical validation rather than publication-only discovery. The broader significance is an intelligence inversion in biomedicine—AI is not just accelerating molecule design, it is re-indexing the drug arsenal already in circulation—pointing to a phase transition where disease starts to look less like an unsolved biological mystery and more like an engineering problem of matching the right intervention to the right failure mode.","createdAt":"2026-06-20T00:31:24.491Z","updatedAt":"2026-06-20T00:31:24.491Z"},{"id":"cmqlmh2t9001go308repsg9v4","exaId":"https://www.nature.com/articles/s41467-026-74451-9","title":"Scalable, fast and accurate differential gene expression testing from millions of cells of multiple patients | Nature Communications","url":"https://www.nature.com/articles/s41467-026-74451-9","source":"www.nature.com","author":null,"publishedAt":"2026-06-19T00:00:00.000Z","summary":"Scalable, fast and accurate differential gene expression testing from millions of cells of multiple patients | Nature Communications\n\n### Subjects\n\n## Abstract\n\nSince the development of DNA microarrays and later RNA bulk sequencing, testing with statistically independent samples has been the standard method for detecting genes with different transcription patterns. Single-cell assays challenge these assumptions because individual cells are statistically dependent, and all proposed methodologies present mathematical limitations or computational bottlenecks that prevent a seamless integration of data from many cells and patients simultaneously. In this work, we solve this crucial limitation by introducing a Bayesian framework that retrieves the independence structure at the level of individu","domain":"VIRTUAL_CELL","significance":"Researchers in *Nature Communications* introduced a Bayesian differential gene-expression framework that scales to millions of single cells across multiple patients, restoring the correct independence structure at the patient level and removing the computational bottlenecks that have limited prior single-cell methods. In the bigger picture, this is the kind of infrastructure shift that makes AI-driven disease science possible: it converts heterogeneous patient-cell data from a statistical obstacle into an engineering substrate, a small but important phase transition in the intelligence inversion of biology where disease becomes more tractable as a systems problem.","createdAt":"2026-06-20T00:31:28.893Z","updatedAt":"2026-06-20T00:31:28.893Z"},{"id":"cmqmc7acq001gr208eiovvorf","exaId":"https://www.biospace.com/press-releases/gri-bio-secures-fda-orphan-drug-designation-for-gri-0621-tazarotene-in-idiopathic-pulmonary-fibrosis","title":"GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis - BioSpace","url":"https://www.biospace.com/press-releases/gri-bio-secures-fda-orphan-drug-designation-for-gri-0621-tazarotene-in-idiopathic-pulmonary-fibrosis","source":"www.biospace.com","author":null,"publishedAt":"2026-06-19T00:00:00.000Z","summary":"GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis - BioSpace\n\n# GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis\n\nJune 18, 2026 |\n\n7 min read\n\nDesignation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity\n\nLA JOLLA, CA, June 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc.(NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a progressive, irreversible","domain":"DRUG_REPURPOSING","significance":"GRI Bio announced that the FDA granted Orphan Drug Designation to GRI-0621 (tazarotene) for idiopathic pulmonary fibrosis, a regulatory milestone that can provide seven years of U.S. market exclusivity if the program succeeds. In The Last Economy frame, this is not an AI breakthrough itself but part of the broader phase transition in medicine: intelligence is being inverted upstream into target selection, molecule design, and patient stratification, turning diseases like fibrosis from open-ended clinical mysteries into engineering problems that computational systems can increasingly attack.","createdAt":"2026-06-20T12:31:42.123Z","updatedAt":"2026-06-20T12:31:42.123Z"},{"id":"cmqj9gq7t001ina08o1melkku","exaId":"https://www.news-medical.net/news/20260617/Deep-learning-identifies-novel-compounds-against-antibiotic-resistant-gonorrhea.aspx","title":"Deep learning identifies novel compounds against antibiotic-resistant gonorrhea","url":"https://www.news-medical.net/news/20260617/Deep-learning-identifies-novel-compounds-against-antibiotic-resistant-gonorrhea.aspx","source":"www.news-medical.net","author":null,"publishedAt":"2026-06-18T00:00:00.000Z","summary":"Deep learning identifies novel compounds against antibiotic-resistant gonorrhea\n\n# Deep learning identifies novel compounds against antibiotic-resistant gonorrhea\n\n- Download PDF Copy\n\nReviewed\n\nWith tens of millions of annual cases, gonorrhea is the second most frequently reported sexually transmitted infection (STI). Alone in the U.S., over 600,000 cases are reported each year. If left untreated, gonorrhea can result in severe reproductive health issues, including infertility in both women and men and pelvic inflammatory disease. The infection also increases the risk of HIV transmission and, if the pathogen spreads from the genitals or throat to other parts of the body, it can damage the heart and cause meningitis and sepsis. The major challenge in more effectively controlling the diseas","domain":"AMR","significance":"A research team reported that deep-learning models can identify novel small-molecule candidates with activity against antibiotic-resistant *Neisseria gonorrhoeae*, extending the search beyond existing antibiotics. The broader significance is that AI is beginning to invert the discovery pipeline: instead of brute-force screening, disease is being treated as a molecular engineering problem in which models learn structure-activity rules and propose compounds directly. In The Last Economy lens, this is an early phase-transition signal in drug R&D, where machine intelligence starts to compress the search space for therapies and changes the economics of curing disease.","createdAt":"2026-06-18T08:51:45.209Z","updatedAt":"2026-06-18T08:51:45.209Z"},{"id":"cmqk736pv001lo108683z3bbh","exaId":"https://www.nature.com/articles/s41698-026-01567-y","title":"Inferring translational efficiency from transcriptomes improves noncanonical neoantigen prioritization and cancer patient stratification | npj Precision Oncology","url":"https://www.nature.com/articles/s41698-026-01567-y","source":"www.nature.com","author":null,"publishedAt":"2026-06-18T00:00:00.000Z","summary":"Inferring translational efficiency from transcriptomes improves noncanonical neoantigen prioritization and cancer patient stratification | npj Precision Oncology\n\nDownload PDF\n\n### Subjects\n\n- Biomarkers\n- Cancer\n- Computational biology and bioinformatics\n- Oncology\n\n## Abstract\n\nAccurate assessment of protein translation is crucial for understanding disease variant functions, but mRNA-protein discrepancy limits transcriptomics-based clinical oncology. While ribosome profiling directly measures translation, its clinical application is constrained by cost and complexity. Deep learning models like Translatomer infer translation efficiency from RNA-seq, but whether in silico translatomes provide superior clinical utility over standard RNA-seq remains unexplored. Here, we present a multidimens","domain":"ONCOLOGY","significance":"The authors of this npj Precision Oncology study report that a deep-learning translatome inferred from standard RNA-seq improves noncanonical neoantigen prioritization and cancer patient stratification relative to transcript abundance alone, addressing the mRNA–protein gap that limits transcriptomics in the clinic. More broadly, this is an intelligence inversion: AI is extracting a harder-to-measure biological state—translation efficiency—from cheaper data, turning cancer into a more tractable engineering problem and moving precision oncology toward a phase where inferred functional state matters more than raw expression counts.","createdAt":"2026-06-19T00:33:00.355Z","updatedAt":"2026-06-19T00:33:00.355Z"},{"id":"cmqk739ut001mo10839qbwp24","exaId":"https://www.biospace.com/press-releases/gero-reaches-34m-in-equity-funding-to-turn-the-physics-of-aging-into-medicines","title":"Gero Reaches $34M in Equity Funding to Turn the Physics of Aging Into Medicines - BioSpace","url":"https://www.biospace.com/press-releases/gero-reaches-34m-in-equity-funding-to-turn-the-physics-of-aging-into-medicines","source":"www.biospace.com","author":null,"publishedAt":"2026-06-18T00:00:00.000Z","summary":"Gero Reaches $34M in Equity Funding to Turn the Physics of Aging Into Medicines - BioSpace\n\nSUBSCRIBE\n\nPress Releases\n\n# Gero Reaches $34M in Equity Funding to Turn the Physics of Aging Into Medicines\n\nJune 17, 2026 |\n\n5 min read\n\nFollowing a Chugai (Roche Group) collaboration with up to $250M in milestones in addition to royalties, and inspired by mammals that defy the rules of aging, Gero uses physics-first AI and human longitudinal data to develop medicines that substantially slow aging and treat age-related diseases.\n\nSINGAPORE & SAN FRANCISCO--(BUSINESS WIRE)--#AI--Gero, which previously secured a collaboration with Chugai Pharmaceutical, a member of the Roche Group, including an upfront payment and up to $250M in milestones in addition to royalties, today announced $17M in new financ","domain":"FUNDING","significance":"Gero announced $34M in equity financing, building on its Chugai/Roche collaboration that includes upfront funding, up to $250M in milestones, and royalties, to develop physics-first AI medicines from human longitudinal data and comparative biology. The significance is that aging is being treated as an engineerable control system: AI is not just finding targets, but inferring the dynamics of decline and intervention, which is the intelligence inversion at the core of disease cure efforts. If this approach works, it marks a phase transition from symptom-and-pathway drug discovery to system-level design of therapies that slow aging and compress multiple age-related diseases at once.","createdAt":"2026-06-19T00:33:04.422Z","updatedAt":"2026-06-19T00:33:04.422Z"},{"id":"cmqkjn1re001hnw08y7ikqb6o","exaId":"https://journals.plos.org/ploscompbiol/article?id=10.1371%2Fjournal.pcbi.1014167","title":"scMagnifier: Resolving fine-grained cell subtypes via GRN-informed perturbations and consensus clustering | PLOS Computational Biology","url":"https://journals.plos.org/ploscompbiol/article?id=10.1371%2Fjournal.pcbi.1014167","source":"journals.plos.org","author":null,"publishedAt":"2026-06-18T00:00:00.000Z","summary":"scMagnifier: Resolving fine-grained cell subtypes via GRN-informed perturbations and consensus clustering | PLOS Computational Biology\n\n- Reader Comments\n- Figures\n\n?\n\n## This is an uncorrected proof.\n\n## Figures\n\n## Abstract\n\nResolving fine-grained cell subtypes in single-cell RNA sequencing (scRNA-seq) data remains challenging, as their subtle transcriptional differences are often obscured by technical noise and data sparsity. Here, we present scMagnifier, a consensus clustering framework that leverages gene regulatory network (GRN)-informed in silico perturbations to amplify subtle transcriptional differences and uncover latent cell subpopulations. scMagnifier perturbs candidate transcription factors (TFs), propagates perturbation effects through cluster-specific GRNs to simulate post-p","domain":"VIRTUAL_CELL","significance":"In PLOS Computational Biology, the scMagnifier team introduced a consensus-clustering framework that uses gene regulatory network–informed in silico transcription-factor perturbations to amplify weak transcriptional signals and resolve fine-grained cell subtypes in sparse scRNA-seq data. The significance is not just better annotation: it is an intelligence inversion from passive cell-state reading to causal, model-based perturbation, pushing single-cell biology toward an engineering discipline in which hidden disease-relevant states can be detected and manipulated. In The Last Economy sense, this is a small but real phase transition in how AI can help cure disease—by turning noisy observational biology into controllable system identification.","createdAt":"2026-06-19T06:24:22.442Z","updatedAt":"2026-06-19T06:24:22.442Z"},{"id":"cmqkjn8wd001jnw0898le6kim","exaId":"https://link.springer.com/article/10.1186/s12859-026-06511-2","title":"A causal reinforcement learning framework for reliable gene regulatory network inference | BMC Bioinformatics | Springer Nature Link","url":"https://link.springer.com/article/10.1186/s12859-026-06511-2","source":"link.springer.com","author":null,"publishedAt":"2026-06-18T00:00:00.000Z","summary":"A causal reinforcement learning framework for reliable gene regulatory network inference | BMC Bioinformatics | Springer Nature Link\n\n# A causal reinforcement learning framework for reliable gene regulatory network inference\n\n- Research\n- Open access\n- Published: 18 June 2026\n\n- Cite this article\n\nYou have full access to this open access article\n\nBMC Bioinformatics Aims and scope Submit manuscript\n\n## Abstract\n\n### Background\n\nGene regulatory network inference is crucial for revealing the mechanisms of cellular functions and the causal mechanisms of disease occurrence. However, traditional correlation-based methods struggle to identify causal directions, and deep learning methods lack structural interpretability. Moreover, neither of them can efficiently adapt to the search of the solution","domain":"VIRTUAL_CELL","significance":"In this BMC Bioinformatics study, the authors introduce a causal reinforcement learning framework for inferring gene regulatory networks, aiming to recover causal direction while preserving structural interpretability—an explicit response to the limitations of correlation-based methods and black-box deep learning. Its significance is that it pushes disease biology toward an intelligence-inversion model, where cellular dysfunction is treated as an engineering and control problem; if these methods scale, they could help make the leap from descriptive genomics to causal, actionable disease intervention—a necessary phase transition for AI-driven medicine.","createdAt":"2026-06-19T06:24:31.694Z","updatedAt":"2026-06-19T06:24:31.694Z"},{"id":"cmqn1xie8001iqv08gyp65e5v","exaId":"https://www.globenewswire.com/news-release/2026/06/18/3314182/0/en/GRI-Bio-Secures-FDA-Orphan-Drug-Designation-for-GRI-0621-Tazarotene-in-Idiopathic-Pulmonary-Fibrosis.html","title":"GRI Bio Secures FDA Orphan Drug Designation for GRI-0621","url":"https://www.globenewswire.com/news-release/2026/06/18/3314182/0/en/GRI-Bio-Secures-FDA-Orphan-Drug-Designation-for-GRI-0621-Tazarotene-in-Idiopathic-Pulmonary-Fibrosis.html","source":"www.globenewswire.com","author":"GRI Bio, Inc.","publishedAt":"2026-06-18T00:00:00.000Z","summary":"GRI Bio Secures FDA Orphan Drug Designation for GRI-0621\n\n# GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis\n\nJune 18, 2026 08:31 ET | Source: GRI Bio, Inc. Follow GRI Bio, Inc.\n\n---\n\nShare\n\n---\n\nDesignation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity\n\nLA JOLLA, CA, June 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc.(NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a progressive, irreversible","domain":"DRUG_REPURPOSING","significance":"GRI Bio announced that the FDA granted orphan drug designation to GRI-0621 (tazarotene) for idiopathic pulmonary fibrosis, a regulatory step that can qualify the program for seven years of U.S. market exclusivity if approved. In the bigger picture, this is not a proof of efficacy, but it is part of the broader shift toward treating disease as an engineering problem: define the target, validate the mechanism, and reduce the friction around deploying precise interventions. In Last Economy terms, it is an incremental marker of the intelligence inversion and the coming phase transition in biomedicine, where AI-accelerated pipelines should make disease-specific programs faster to design, test, and commercialize.","createdAt":"2026-06-21T00:31:56.000Z","updatedAt":"2026-06-21T00:31:56.000Z"},{"id":"cmqk72ol9001ho108f8zpy8om","exaId":"https://theneuralfeed.com/article/multiscale-reconstruction-of-protein-conformations-from-cryo-em-images/9862JVus","title":"New multiscale algorithm reconstructs protein structures... | The Neural Feed","url":"https://theneuralfeed.com/article/multiscale-reconstruction-of-protein-conformations-from-cryo-em-images/9862JVus","source":"theneuralfeed.com","author":null,"publishedAt":"2026-06-17T00:00:00.000Z","summary":"New multiscale algorithm reconstructs protein structures... | The Neural Feed\n\nImage & Video\n\n# New multiscale algorithm reconstructs protein structures from noisy cryo-EM images with SOTA accuracy\n\n⚡Using explicit protein backbone priors, this method beats standard approaches on noise and contrast.\n\nDeep Dive\n\nA team from KTH Royal Institute of Technology (David Y. W. Thong, Ozan Öktem, Joakim Andén) has developed a novel multiscale algorithm for directly recovering atomic protein structures from single-particle cryo-EM images. The method goes beyond traditional approaches by explicitly representing the protein backbone in terms of bonds, torsion angles, and bond angles. This provides rich prior information that makes the reconstruction robust to high noise, low contrast, and even misspec","domain":"PROTEIN_FOLDING","significance":"Researchers at KTH Royal Institute of Technology — David Y. W. Thong, Ozan Öktem, and Joakim Andén — reported a multiscale algorithm that reconstructs atomic protein structures directly from noisy single-particle cryo-EM images by encoding backbone priors in bonds, torsion angles, and bond angles, achieving state-of-the-art robustness under low contrast and missing data. This matters because structural biology is a core bottleneck in AI-enabled drug discovery: better inverse reconstruction turns weak, noisy measurements into usable molecular models, an example of intelligence inversion where prior knowledge and inference replace brute-force observation. In the Last Economy frame, that is a small but concrete phase transition toward treating disease as an engineering problem—one where molecular structure can be recovered, modeled, and ultimately targeted with increasing precision.","createdAt":"2026-06-19T00:32:36.861Z","updatedAt":"2026-06-19T00:32:36.861Z"},{"id":"cmqies0as001hmn08fdphngbx","exaId":"https://thedatastory.substack.com/p/how-to-make-drugs-with-ai","title":"HOW TO MAKE DRUGS WITH AI - by Justin Evans - The DataStory","url":"https://thedatastory.substack.com/p/how-to-make-drugs-with-ai","source":"thedatastory.substack.com","author":"Justin Evans","publishedAt":"2026-06-17T00:00:00.000Z","summary":"HOW TO MAKE DRUGS WITH AI - by Justin Evans - The DataStory\n\nSubscribeSign in\n\n# HOW TO MAKE DRUGS WITH AI\n\n### Case Study: Isomorphic Labs, a $2.1B Spinoff of AlphaFold\n\nJun 17, 2026\n\n2\n\nShare\n\n# EDITOR’S NOTE\n\nI was aware of AlphaFold… aware that the founders won the Nobel Prize… but it was always on my to-do list to understand what exactly protein folding is; how AI helped; what the heck “diffusion models” are.\n\nWhen Isomorphic Labs raised its huge round last month, I took it as my cue to finally understand this space--or try to. Below is the result of that research. A note: there are so many terms of art in this space that I have bolded them to distinguish them from the other clever metaphors we employ otherwise.\n\nLet’s dig in.\n\n## 1. I WANT A NEW DRUG\n\nMaking a new drug is one of the","domain":"DRUG_DESIGN","significance":"Justin Evans reports on Isomorphic Labs, the $2.1B AlphaFold spinoff, and its attempt to use AI—building on protein-structure prediction and diffusion-style generative models—to design drug candidates rather than just analyze biology. The significance is that this pushes AI from biological description into intervention synthesis: a phase transition from tool-assisted science to intelligence inversion, where the model searches the chemical and protein design space to solve disease as an engineering problem.","createdAt":"2026-06-17T18:32:43.396Z","updatedAt":"2026-06-17T18:32:43.396Z"},{"id":"cmqj4lp1t001ho208fup4c6bq","exaId":"https://www.prnewswire.com/news-releases/insilico-completes-first-in-human-dosing-in-phase-i-clinical-study-of-ai-driven-nlrp3-inhibitor-ism8969-achieving-first-clinical-milestone-in-collaboration-with-hygtia-therapeutics-302802955.html","title":"Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics","url":"https://www.prnewswire.com/news-releases/insilico-completes-first-in-human-dosing-in-phase-i-clinical-study-of-ai-driven-nlrp3-inhibitor-ism8969-achieving-first-clinical-milestone-in-collaboration-with-hygtia-therapeutics-302802955.html","source":"www.prnewswire.com","author":"Insilico Medicine","publishedAt":"2026-06-17T00:00:00.000Z","summary":"Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics Accessibility Statement Skip Navigation\n\nCAMBRIDGE, Mass. and HONG KONG, June 17, 2026 /PRNewswire/ -- Insilico Medicine (\"Insilico\", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration with Hygtia Therapeutics with the completion of first-in-human dosing in the Phase I study of ISM8969. ISM8969 is a potentially best-in-class, orally available, brain-penetrant small-molecule inhibitor of the NLRP3 inflammasome being developed to treat chronic neuroinflammation and","domain":"DRUG_DESIGN","significance":"Insilico Medicine, in collaboration with Hygtia Therapeutics, announced first-in-human dosing in the Phase I study of ISM8969, an AI-designed, orally available, brain-penetrant NLRP3 inflammasome inhibitor for chronic neuroinflammation. The significance is not the molecule alone but the proof that generative AI can carry a target from design into clinical testing, marking an intelligence inversion in drug discovery: model-led engineering replacing purely human hypothesis generation. In Last Economy terms, this is a small but real phase transition toward treating disease as a systems engineering problem, where AI compresses the path from biological mechanism to intervenable therapy.","createdAt":"2026-06-18T06:35:38.897Z","updatedAt":"2026-06-18T06:35:38.897Z"},{"id":"cmqirmwui001hp508b5ywo99f","exaId":"https://www.moomoo.com/hans/news/post/71667891/insilico-completes-first-in-human-dosing-in-phase-i-clinical","title":"Insilico已完成其与Hygtia Therapeutics合作的AI驱动型NLRP3抑制剂ISM8969的I期临床研究中的首个人体给药，达成首个临床里程碑。","url":"https://www.moomoo.com/hans/news/post/71667891/insilico-completes-first-in-human-dosing-in-phase-i-clinical","source":"www.moomoo.com","author":null,"publishedAt":"2026-06-17T00:00:00.000Z","summary":"Insilico已完成其与Hygtia Therapeutics合作的AI驱动型NLRP3抑制剂ISM8969的I期临床研究中的首个人体给药，达成首个临床里程碑。\n\nトップに戻る\n\n# Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration With Hygtia Therapeutics\n\nInsilico已完成其与Hygtia Therapeutics合作的AI驱动型NLRP3抑制剂ISM8969的I期临床研究中的首个人体给药，达成首个临床里程碑。\n\nPR Newswire· 06/17 21:00\n\nCAMBRIDGE, Mass. and HONG KONG, June 17, 2026 /PRNewswire/ -- Insilico Medicine (\"Insilico\", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration with Hygtia Therapeutics with the completion of first-in-human dosing in the Phase I study of ISM8969. ISM8969 is a poten","domain":"DRUG_DESIGN","significance":"Insilico Medicine announced that it has completed first-in-human dosing of ISM8969, an AI-driven NLRP3 inhibitor, in a Phase I study with Hygtia Therapeutics, marking the program’s first clinical milestone. The significance is that a generative-AI-designed molecule has crossed from computational target design into human testing, a concrete step in the broader shift from biology as a discovery bottleneck to disease as an engineering problem. In The Last Economy terms, this is an intelligence inversion and an early phase transition: AI is beginning to compress the path from hypothesis to clinic in areas where traditional drug development has been too slow and expensive.","createdAt":"2026-06-18T00:32:40.650Z","updatedAt":"2026-06-18T00:32:40.650Z"},{"id":"cmqirn0vq001ip508dh6mn4zm","exaId":"https://journals.plos.org/ploscompbiol/article?id=10.1371%2Fjournal.pcbi.1014422","title":"Deciphering cell type-specific causal genetic effects on brain imaging-derived phenotypes and disorders with single-cell Mendelian randomization | PLOS Computational Biology","url":"https://journals.plos.org/ploscompbiol/article?id=10.1371%2Fjournal.pcbi.1014422","source":"journals.plos.org","author":null,"publishedAt":"2026-06-17T00:00:00.000Z","summary":"Deciphering cell type-specific causal genetic effects on brain imaging-derived phenotypes and disorders with single-cell Mendelian randomization | PLOS Computational Biology\n\n## This is an uncorrected proof.\n\n## Figures\n\n## Abstract\n\nReconstructing causality routes from genetic effects to complex phenotypes in particular cell types is crucial for understanding biological mechanisms underlying the brain-associated phenotypes including imaging-derived phenotypes (IDPs), and brain disorders and behaviors (DBs). Here, we develop a single-cell Mendelian randomization framework to infer cell type-specific causal relationships between gene expression and diverse brain-associated complex phenotypes by integrating single-cell expression quantitative trait loci (cis-eQTLs) and genome-wide associatio","domain":"VIRTUAL_CELL","significance":"In PLOS Computational Biology, the authors report a single-cell Mendelian randomization framework that integrates single-cell cis-eQTLs with GWAS data to infer cell type-specific causal effects of gene expression on brain imaging-derived phenotypes, disorders, and behaviors. The result is an intelligence inversion from association-heavy neurogenetics to machine-assisted causal mapping at cellular resolution, advancing the phase transition in which disease becomes an engineering problem: identify the causal cell state, then design the intervention.","createdAt":"2026-06-18T00:32:45.878Z","updatedAt":"2026-06-18T00:32:45.878Z"},{"id":"cmqirnb1x001jp50808j2ocs8","exaId":"https://www.insideprecisionmedicine.com/topics/informatics/ai-discovers-two-new-antibiotics-for-drug-resistant-gonorrhea/","title":"AI Discovers Two New Antibiotics for Drug-Resistant Gonorrhea | Inside Precision Medicine","url":"https://www.insideprecisionmedicine.com/topics/informatics/ai-discovers-two-new-antibiotics-for-drug-resistant-gonorrhea/","source":"www.insideprecisionmedicine.com","author":"Clara Rodriguez Fernandez","publishedAt":"2026-06-17T00:00:00.000Z","summary":"AI Discovers Two New Antibiotics for Drug-Resistant Gonorrhea | Inside Precision Medicine\n\nSubscribe\n\n- Get Inside Precision Medicine Magazine\n- Get Inside Precision Medicine eNewsletters\n\nSearch\n\nSign in\n\nWelcome! Log into your account\n\nyour username\n\nyour password\n\nForgot your password? Get help\n\nPassword recovery\n\nRecover your password\n\nyour email\n\nA password will be e-mailed to you.\n\n# Inside Precision Medicine\n\nInside Precision Medicine Informatics AI Discovers Two New Antibiotics for Drug-Resistant Gonorrhea\n\nShare\n\nCredit: RUSLANAS BARANAUSKAS/ Science Photo Library / Getty Images\n\nScientists have developed a deep learning model that could significantly accelerate the discovery of novel antibiotic compounds. In a study published today in Science Translational Medicine, the AI algori","domain":"AMR","significance":"An MIT-led team reported in *Science Translational Medicine* that a deep-learning model identified two novel antibiotic candidates with activity against drug-resistant *Neisseria gonorrhoeae*, with preclinical validation supporting their potential. More broadly, it is an intelligence inversion in drug R&D: AI is shifting antibiotic discovery from low-throughput empirical screening toward model-driven search over chemical space, a possible phase transition in treating disease as an engineering problem.","createdAt":"2026-06-18T00:32:59.060Z","updatedAt":"2026-06-18T00:32:59.060Z"},{"id":"cmqirni81001lp508qtmux05d","exaId":"https://www.genengnews.com/topics/artificial-intelligence/merck-protillion-launch-ai-drug-discovery-collaboration-with-up-to-510m-in-milestone-payments/","title":"Merck, Protillion Launch AI Drug Discovery Collaboration with Up-to-$510M in Milestone Payments","url":"https://www.genengnews.com/topics/artificial-intelligence/merck-protillion-launch-ai-drug-discovery-collaboration-with-up-to-510m-in-milestone-payments/","source":"www.genengnews.com","author":"Alex Philippidis","publishedAt":"2026-06-17T00:00:00.000Z","summary":"Merck, Protillion Launch AI Drug Discovery Collaboration with Up-to-$510M in Milestone Payments https://www.genengnews.com/genprowebdirectory\n\nGEN Edge\n\n- Featured News\n- Multimedia\n\nContent\n\n- News\n- Insights\n\nTopics\n\n- Artificial Intelligence\n- Bioprocessing\n- Cancer\n- Drug Discovery\n- Genome Editing\n- Infectious Diseases\n- OMICs\n- Translational Medicine\n\nMultimedia\n\nResources\n\n- GEN Biotechnology\n- Re:Gen Open\n\nSubscribe\n\n- Get GEN Magazine\n- Get GEN eNewsletters\n\nSearch\n\nSign in\n\nWelcome! Log into your account\n\nyour username\n\nyour password\n\nForgot your password? Get help\n\nPrivacy Policy\n\nPassword recovery\n\nRecover your password\n\nyour email\n\nA password will be e-mailed to you.\n\nGEN – Genetic Engineering and Biotechnology News\n\nHome Topics Artificial Intelligence Merck, Protillion Launch","domain":"FUNDING","significance":"Merck and Protillion announced an AI drug-discovery collaboration that could be worth up to $510 million in milestones, with Protillion applying its computational platform to help Merck identify and optimize new therapeutic candidates. The significance is less the dollar figure than the operating model: disease discovery is moving from trial-and-error chemistry toward intelligence-driven search, an inversion in which machine learning helps navigate biological design space as an engineering problem. If these platforms scale, they could mark a phase transition in how medicines are found, making AI a core instrument for curing disease rather than just supporting it.","createdAt":"2026-06-18T00:33:08.354Z","updatedAt":"2026-06-18T00:33:08.354Z"},{"id":"cmqirnlhg001mp5080tqqm622","exaId":"https://www.prnewswire.com/news-releases/triveni-bio-raises-65-million-series-c-financing-to-expand-scope-of-first-in-class-bispecific-triv-573-clinical-studies-and-drive-next-stage-company-growth-302802546.html","title":"Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth","url":"https://www.prnewswire.com/news-releases/triveni-bio-raises-65-million-series-c-financing-to-expand-scope-of-first-in-class-bispecific-triv-573-clinical-studies-and-drive-next-stage-company-growth-302802546.html","source":"www.prnewswire.com","author":"Triveni Bio","publishedAt":"2026-06-17T00:00:00.000Z","summary":"Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth Accessibility Statement Skip Navigation\n\n— Series C supported by premier syndicate including co-leads Ascenta Capital and Janus Henderson Investors with significant participation from Deep Track plus existing investors —\n\n— Fundingenables larger Phase 2 clinical proof-of-concept trial evaluating IL-13 and KLK5/7 dual-targeting antibody in atopic dermatitis —\n\n— Evan Rachlin, M.D., Co-Founder and Managing Partner of Ascenta Capital, joins the Board of Directors —\n\nWATERTOWN, Mass., June 17, 2026 /PRNewswire/ -- Triveni Bio Inc., a clinical-stage biotechnology company advancing novel antibody treatments for immunological and inflammatory","domain":"FUNDING","significance":"Triveni Bio announced a $65 million Series C led by Ascenta Capital and Janus Henderson Investors, with participation from Deep Track and existing backers, to expand the Phase 2 proof-of-concept program for TRIV-573, a first-in-class bispecific antibody targeting IL-13 and KLK5/7 in atopic dermatitis; Ascenta co-founder Evan Rachlin also joins the board. More broadly, the raise reflects the phase transition in medicine from treating disease as a diffuse biological mystery to an engineering problem centered on specific pathways, where AI increasingly matters as the intelligence layer for target selection, molecule design, and patient stratification.","createdAt":"2026-06-18T00:33:12.581Z","updatedAt":"2026-06-18T00:33:12.581Z"},{"id":"cmqj4lrpw001io208g4y7iyhd","exaId":"https://world.storm.mg/articles/1142465","title":"Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics | PR Newswire | Business - The Storm Media","url":"https://world.storm.mg/articles/1142465","source":"world.storm.mg","author":"PR Newswire","publishedAt":"2026-06-17T00:00:00.000Z","summary":"Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics | PR Newswire | Business - The Storm Media\n\n# Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics\n\n2026-06-17 21:00\n\n2026-06-17 21:00\n\nInsilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics\n\nCAMBRIDGE, Mass. and HONG KONG, June 17, 2026 /PRNewswire/ -- Insilico Medicine (\"Insilico\", HKEX: 3696), a clinical-stage biotechnology company powered by generative art","domain":"DRUG_DESIGN","significance":"Insilico Medicine, in collaboration with Hygtia Therapeutics, announced first-in-human dosing of ISM8969, an AI-designed NLRP3 inhibitor, in a Phase I clinical study—the program’s first clinical milestone. This matters because it moves generative AI from target and molecule design into human pharmacology, a concrete step in the “intelligence inversion” of drug discovery where machine-generated hypotheses begin to traverse the hardest boundary in biomedicine.\n\nFrom a Last Economy perspective, this is another sign of the phase transition in which disease is treated less as an intractable biological mystery and more as an engineering problem: identify a mechanism, design a molecular intervention, and test it empirically in patients.","createdAt":"2026-06-18T06:35:42.356Z","updatedAt":"2026-06-18T06:35:42.356Z"},{"id":"cmqj4lvof001jo208vo6v23yi","exaId":"https://endpoints.news/in-second-reversal-fda-gives-uniqure-a-green-light-to-seek-accelerated-approval/","title":"In second reversal, FDA gives uniQure a green light to seek accelerated approval","url":"https://endpoints.news/in-second-reversal-fda-gives-uniqure-a-green-light-to-seek-accelerated-approval/","source":"endpoints.news","author":null,"publishedAt":"2026-06-17T00:00:00.000Z","summary":"In second reversal, FDA gives uniQure a green light to seek accelerated approval\n\nShare on LinkedIn Share on Twitter\n\nJune 17, 2026 11:40 AM EDTUpdated 02:01 PM\n\nR&D\n\nCell/Gene Tx\n\nFDA+\n\n# In an­oth­er re­ver­sal, FDA gives uniQure ac­cel­er­at­ed ap­proval path for Hunt­ing­ton's gene ther­a­py\n\n### Max Gelman\n\nSee all stories by Max Gelman\n\n#### Senior Editor\n\nReg­u­la­to­ry flex­i­bil­i­ty ap­pears to be back on the FDA’s menu fol­low­ing the de­par­tures of Mar­ty Makary and Vinay Prasad.\n\nAt the cen­ter of the de­bate, once again, is the rare dis­ease biotech uniQure and its ex­per­i­men­tal gene ther­a­py for Hunt­ing­ton’s dis­ease. The FDA has walked back its pre­vi­ous about-face, uniQure an­nounced Wednes­day morn­ing, and will al­low the com­pa­ny to seek ac­cel­er­at­ed ap­prov","domain":"DRUG_REPURPOSING","significance":"The FDA told uniQure it may seek accelerated approval for its experimental Huntington’s disease gene therapy, reversing an earlier setback and restoring a path to submit on biomarker-linked evidence rather than waiting for a complete long-term outcomes package. In The Last Economy frame, that is a small but material shift toward treating disease as an engineering problem with regulatory plumbing that can be optimized by AI-enabled design, modeling, and trial execution—an example of intelligence inversion moving from discovery to deployable medicine.","createdAt":"2026-06-18T06:35:47.488Z","updatedAt":"2026-06-18T06:35:47.488Z"},{"id":"cmqj4m3g8001ko208a8733pz7","exaId":"https://wyss.harvard.edu/news/machine-learning-how-to-overcome-antibiotic-resistant-gonorrhea/","title":"Machine-learning how to overcome antibiotic-resistant gonorrhea","url":"https://wyss.harvard.edu/news/machine-learning-how-to-overcome-antibiotic-resistant-gonorrhea/","source":"wyss.harvard.edu","author":null,"publishedAt":"2026-06-17T00:00:00.000Z","summary":"Machine-learning how to overcome antibiotic-resistant gonorrhea\n\nSearch\n\n## AI-enabled antibiotic discovery proves effective at identifying new chemical structures and targets in the constant fight against antibiotic-resistant gonorrhea\n\nBy Benjamin Boettner\n\nGonorrhea, which is caused by the bacterial pathogen Neisseria gonorrhoeae, is one of the most-often occurring sexually transmitted infections resulting in a plethora of health issues. Credit: Shutterstock/ESB Professional\n\n(BOSTON) — With tens of millions of annual cases, gonorrhea is the second most frequently reported sexually transmitted infection (STI). In the U.S. alone, over 600,000 cases are reported each year. If left untreated, gonorrhea can result in severe reproductive health issues, including infertility in both women and","domain":"AMR","significance":"Researchers at Boston University reported that machine-learning models could identify previously unseen antibiotic-like chemical structures and candidate targets active against *Neisseria gonorrhoeae*, the drug-resistant bacterium behind gonorrhea. The result matters because it shows the intelligence inversion at the center of AI medicine: instead of brute-force screening, antibiotic discovery is becoming an engineering search problem, a sign that disease treatment may be approaching a phase transition from empirical chemistry to model-guided design.","createdAt":"2026-06-18T06:35:57.559Z","updatedAt":"2026-06-18T06:35:57.559Z"},{"id":"cmqj4m6hg001lo208zck7bei2","exaId":"https://www.morningstar.com/news/pr-newswire/20260617cn85969/insilico-completes-first-in-human-dosing-in-phase-i-clinical-study-of-ai-driven-nlrp3-inhibitor-ism8969-achieving-first-clinical-milestone-in-collaboration-with-hygtia-therapeutics","title":"Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics | Morningstar","url":"https://www.morningstar.com/news/pr-newswire/20260617cn85969/insilico-completes-first-in-human-dosing-in-phase-i-clinical-study-of-ai-driven-nlrp3-inhibitor-ism8969-achieving-first-clinical-milestone-in-collaboration-with-hygtia-therapeutics","source":"www.morningstar.com","author":null,"publishedAt":"2026-06-17T00:00:00.000Z","summary":"Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics | Morningstar\n\nSign In\n\nInsilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics\n\n## Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics\n\nPR Newswire\n\nCAMBRIDGE, Mass. and HONG KONG, June 17, 2026\n\nCAMBRIDGE, Mass. and HONG KONG, June 17, 2026 /PRNewswire/ -- Insilico Medicine (\"Insilico\", HKEX: 3696), a clinical-stage biotechnology company powered by generativ","domain":"CLINICAL_TRIALS","significance":"Insilico Medicine, in collaboration with Hygtia Therapeutics, announced first-in-human dosing in Phase I of ISM8969, an AI-driven NLRP3 inhibitor, marking the program’s first clinical milestone. More importantly, it shows AI-designed drug candidates crossing from in silico target-to-molecule generation into human pharmacology, a concrete intelligence inversion in which computation increasingly leads bench discovery. In Last Economy terms, this is a phase-transition signal: inflammatory disease is being treated less as an empirical search problem and more as an engineering problem with compressed design, validation, and translation loops.","createdAt":"2026-06-18T06:36:01.492Z","updatedAt":"2026-06-18T06:36:01.492Z"},{"id":"cmqj4m8le001mo2086xjyx5zs","exaId":"https://www.news-medical.net/news/20260617/AI-designed-drug-for-Parkinsons-begins-first-human-trial.aspx","title":"AI-designed drug for Parkinson's begins first human trial","url":"https://www.news-medical.net/news/20260617/AI-designed-drug-for-Parkinsons-begins-first-human-trial.aspx","source":"www.news-medical.net","author":null,"publishedAt":"2026-06-17T00:00:00.000Z","summary":"AI-designed drug for Parkinson's begins first human trial\n\n# AI-designed drug for Parkinson's begins first human trial\n\n- Download PDF Copy\n\nReviewed\n\nInsilico Medicine (\"Insilico\", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration with Hygtia Therapeutics with the completion of first-in-human dosing in the Phase I study of ISM8969. ISM8969 is a potentially best-in-class, orally available, brain-penetrant small-molecule inhibitor of the NLRP3 inflammasome being developed to treat chronic neuroinflammation and central nervous system (CNS) disorders, including Parkinson's disease.\n\nAs the first study in the clinical development of ISM8969, thi","domain":"CLINICAL_TRIALS","significance":"Insilico Medicine announced first-in-human dosing in Phase I for ISM8969, an AI-designed, orally available, brain-penetrant NLRP3 inflammasome inhibitor co-developed with Hygtia Therapeutics for Parkinson’s disease and other CNS disorders. The significance is that a generative-AI design pipeline is now producing clinical-stage molecules for neurodegeneration, moving AI from pattern recognition to intervention design and testing—a concrete step in the broader shift from treating disease as a descriptive biology problem to an engineering problem. In Last Economy terms, this is an intelligence inversion marker: AI is increasingly upstream of therapeutic discovery, and the field is approaching a phase transition from hypothesis-led pharmacology to machine-generated medicine.","createdAt":"2026-06-18T06:36:04.226Z","updatedAt":"2026-06-18T06:36:04.226Z"},{"id":"cmqj9gk6e001hna08svt7gjm7","exaId":"https://www.pharmasalmanac.com/articles/insilico-completes-first-in-human-dosing-in-phase-i-clinical-study-of-ai-driven-nlrp3-inhibitor-ism8969","title":"Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969","url":"https://www.pharmasalmanac.com/articles/insilico-completes-first-in-human-dosing-in-phase-i-clinical-study-of-ai-driven-nlrp3-inhibitor-ism8969","source":"www.pharmasalmanac.com","author":null,"publishedAt":"2026-06-17T00:00:00.000Z","summary":"Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969\n\nLog in\n\nSubscribe\n\nLog in\n\n## Subscribe for the Newsletter\n\n- Articles\n- Expert Interviews\n- Roundtable\n- Press Releases\n- Videos\n- The Road To Experience\n- Market Research\n- Directory\n\nClose\n\n- Discovery\n- Small Molecules\n- Biologics\n- Advanced Therapies\n- Manufacturing\n- Supply Chain\n- Clinical Trials\n- Technologies\n- Financing\n\n# Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969\n\nInsilico Medicine\n\nJun 17, 2026PR-06-26-01\n\nClinical Trials Press Releases Artificial Intelligence Neurology Drug Discovery and Development Neurodegenerative\n\nCAMBRIDGE, Mass. and HONG KONG -- Insilico Medicine (\"Insilico\", HKEX: 3696), a clinical-stage b","domain":"DRUG_DESIGN","significance":"Insilico Medicine announced first-in-human dosing in its Phase I study of ISM8969, an AI-discovered NLRP3 inhibitor, marking the program’s transition from computational design into clinical testing. In The Last Economy terms, this is an intelligence inversion moment: AI is no longer just interpreting biology, but designing interventions against disease pathways treated as engineering problems. It is a small but important phase transition on the path from model-generated targets to medicines that can be validated in humans.","createdAt":"2026-06-18T08:51:37.382Z","updatedAt":"2026-06-18T08:51:37.382Z"},{"id":"cmqk72tsm001io108jru4k2r4","exaId":"https://www.linkedin.com/pulse/insilico-completes-first-in-human-dosing-phase-i-clinical-axzzc","title":"Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969 with Hygtia Therapeutics","url":"https://www.linkedin.com/pulse/insilico-completes-first-in-human-dosing-phase-i-clinical-axzzc","source":"www.linkedin.com","author":null,"publishedAt":"2026-06-17T00:00:00.000Z","summary":"Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969 with Hygtia Therapeutics\n\nAgree & Join LinkedIn\n\nBy clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.\n\nInsilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969 with Hygtia Therapeutics\n\nInsilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics\n\nCAMBRIDGE, Mass. / HONG KONG — [Date] — Insilico Medicine (“Insilico”, HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first","domain":"DRUG_DESIGN","significance":"Insilico Medicine, in collaboration with Hygtia Therapeutics, announced first-in-human dosing in the Phase I study of ISM8969, an AI-designed NLRP3 inhibitor, marking its first clinical milestone. The significance is that a generative model has now produced a molecule that has entered human testing, a concrete sign of intelligence inversion in drug discovery: AI is no longer just analyzing biology, but helping engineer interventions against it. In The Last Economy terms, this is an early phase-transition signal that disease is becoming an engineering problem—one where target selection, molecule design, and clinical validation are increasingly coupled in a machine-accelerated loop.","createdAt":"2026-06-19T00:32:43.607Z","updatedAt":"2026-06-19T00:32:43.607Z"},{"id":"cmqk73296001ko108y8akmxei","exaId":"https://www.gsk.com/en-gb/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adults-with-complicated-urinary-tract-infections-cutis/","title":"Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) | GSK","url":"https://www.gsk.com/en-gb/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adults-with-complicated-urinary-tract-infections-cutis/","source":"www.gsk.com","author":null,"publishedAt":"2026-06-17T00:00:00.000Z","summary":"Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) | GSK\n\n17 June 2026\n\nFor media and investors only\n\n# Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)\n\nDownload (PDF - 239.1KB)\n\n- First and only oral carbapenem antibiotic approved in the US\n- Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1\n- More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3\n\nGSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tr","domain":"AMR","significance":"GSK and Spero Therapeutics announced FDA approval of Utebzi (tebipenem pivoxil), the first and only oral carbapenem approved in the US for adults with complicated urinary tract infections, supported by a PIVOT-PO non-inferiority trial versus intravenous therapy. More broadly, this is an engineering response to antimicrobial resistance: moving a last-line antibiotic class from infusion to oral delivery changes the treatment architecture for a large, resistant-disease population. In The Last Economy frame, it is a modest but real phase transition in disease control, and a signal of the intelligence inversion that AI-driven drug design aims to accelerate—turning hard-to-treat infections into solvable systems problems.","createdAt":"2026-06-19T00:32:54.570Z","updatedAt":"2026-06-19T00:32:54.570Z"},{"id":"cmqmp1qef001gqs088jqsvwz6","exaId":"https://link.springer.com/article/10.1186/s13040-026-00577-7","title":"Navigating the uncharted: AI-driven advances in protein structure, dynamics, interactions and ligand interactions for understudied families | BioData Mining | Springer Nature Link","url":"https://link.springer.com/article/10.1186/s13040-026-00577-7","source":"link.springer.com","author":null,"publishedAt":"2026-06-17T00:00:00.000Z","summary":"Navigating the uncharted: AI-driven advances in protein structure, dynamics, interactions and ligand interactions for understudied families | BioData Mining | Springer Nature Link\n\n# Navigating the uncharted: AI-driven advances in protein structure, dynamics, interactions and ligand interactions for understudied families\n\n- Review\n- Open access\n- Published: 17 June 2026\n\n- Cite this article\n\nYou have full access to this open access article\n\nDownload PDF\n\nSave article\n\nView saved research\n\nBioData Mining Aims and scope Submit manuscript\n\n## Abstract\n\nThe structural and functional characterization of lesser-known protein families remains a major challenge in modern computational biology. Recent breakthroughs in artificial intelligence (AI) and machine learning (ML) have rapidly advanced thes","domain":"PROTEIN_FOLDING","significance":"In a Springer Nature review in *BioData Mining*, the authors survey how recent AI/ML methods are extending protein-structure, dynamics, interaction, and ligand-binding prediction to understudied protein families that have been hard to characterize experimentally. The significance is not a single target discovery but an intelligence inversion: models are beginning to supply mechanistic priors where biology has been sparse, narrowing the search space for drugs and turning disease biology from an observational problem into an engineering one. That is the phase transition in AI-for-biomedicine: from describing proteins after the fact to systematically mapping and perturbing the molecular systems that make disease possible.","createdAt":"2026-06-20T18:31:17.991Z","updatedAt":"2026-06-20T18:31:17.991Z"},{"id":"cmqn1xmv6001jqv08o1hw7amk","exaId":"https://www.nature.com/articles/s41586-026-10660-y","title":"Spatial distribution of the proteome in the human body and in cancers | Nature","url":"https://www.nature.com/articles/s41586-026-10660-y","source":"www.nature.com","author":null,"publishedAt":"2026-06-17T00:00:00.000Z","summary":"Spatial distribution of the proteome in the human body and in cancers | Nature\n\nDownload PDF\n\n### Subjects\n\n- Proteomics\n- Systems analysis\n- Target identification\n- Tumour biomarkers\n\n## Abstract\n\nA detailed, spatially resolved quantitative map of the human proteome is essential for a deeper understanding of human biology and disease1,2,3, 4. Here we present a comprehensive human proteomic landscape, generated by profiling more than 13,000 proteins across 2,856 samples using data-independent acquisition mass spectrometry. The dataset spans 58 major tissue types, 251 specific tissue subtypes and 25 distinct carcinomas. This resource enables the depiction of spatially resolved proteome trajectories across tissue types and physiological states, including fetal, tumour, adjacent non-tumour an","domain":"ONCOLOGY","significance":"Researchers reporting in *Nature* built a spatially resolved quantitative atlas of the human proteome, profiling more than 13,000 proteins across 2,856 samples from 58 tissue types and 25 carcinomas. The result is a tissue- and cancer-specific reference map for target identification, biomarker discovery, and proteome trajectory analysis across normal, fetal, adjacent non-tumor, and tumor states. In The Last Economy terms, this is an intelligence inversion: biology is being converted into machine-readable structure, a prerequisite phase transition for treating disease as an engineering problem rather than a purely descriptive one.","createdAt":"2026-06-21T00:32:01.794Z","updatedAt":"2026-06-21T00:32:01.794Z"}],"total":146,"digest":{"id":"cmqnromn2001is308te3l2yyd","breakthroughTitle":"AI-designed therapies crossed new clinical and regulatory thresholds","breakthroughSummary":"The week’s signal is translational: AI is no longer confined to target-finding or paper-level prediction, but is increasingly reaching dosing, pivotal enrollment, and regulatory de-risking. Just as important, new single-cell, causal, and experimental platforms are improving the data substrate, making cure-oriented engineering more tractable across cardio-heme, pulmonary, oncology, and infectious disease frontiers.","topStories":[{"title":"Trial Updates","items":["CureGene dosed the first participant in the U.S. pivotal trial of Evategrel (CG-0255), advancing its antiplatelet program toward NDA readiness.","Insilico Medicine reported first-in-human dosing of ISM8969, an AI-designed NLRP3 inhibitor, marking a key Phase I clinical milestone in chronic neuroinflammation."]},{"title":"Regulatory and Pipeline Shifts","items":["GRI Bio received FDA Orphan Drug Designation for GRI-0621 (tazarotene) in idiopathic pulmonary fibrosis, strengthening the program’s development path and exclusivity outlook.","Merck and Protillion expanded their AI drug-discovery collaboration, signaling continued pharmaceutical capital flow toward model-driven candidate generation and optimization."]},{"title":"Breakthrough Discovery Signals","items":["Deep learning mined prion-related proteins for 1,179 candidate antimicrobial peptides, with synthesized hits showing antibacterial activity and in vivo benefit against Acinetobacter infection in mice.","Another AI-enabled effort identified novel small-molecule candidates active against drug-resistant Neisseria gonorrhoeae, extending antibiotic discovery beyond legacy chemotypes."]},{"title":"Data and Causal Biology Infrastructure","items":["Single-cell and virtual-cell methods advanced: a Bayesian differential expression framework scaled to millions of cells across patients, removing a major analytical bottleneck.","New causal and GRN-informed methods improved cell subtype resolution and causal inference, including single-cell Mendelian randomization and reinforcement-learning-based network inference.","In oncology, deep-learning-derived translatome inference improved noncanonical neoantigen prioritization and patient stratification from standard RNA-seq."]},{"title":"Platform and Enabling Investment","items":["Portal Biotechnologies closed an oversubscribed $9 million round and expanded its DARPA contract, underscoring demand for experimental infrastructure that feeds AI-driven drug discovery and cell therapy.","Gero raised $34 million to advance physics-first AI medicines using longitudinal human data, reinforcing investment in system-level approaches to aging and multimorbidity."]}],"deepDive":null,"fundingDeals":null,"watchList":[],"numbersMatter":null,"generatedAt":"2026-06-21T12:32:51.614Z","weekOf":"2026-06-21T00:00:00.000Z","numbersThatMatter":[]}}